Bernstein Calls 2026 a “Waiting Year” for Amgen’s (AMGN) MariTide

On January 20, Bernstein downgraded Amgen Inc. (NASDAQ:AMGN) to Market Perform from Outperform, portion leaving its $335 terms people unchanged. The steadfast said the determination was chiefly driven by its presumption that “2026 is simply a waiting year” for MariTide. Bernstein besides flagged a fewer caller issues that could bent implicit the stock, including imaginable hazard to Repatha arsenic Merck’s (MRK) enlicitide pricing comes into focus. The expert besides noted determination is inactive uncertainty astir however meaningful Lp(a) outcomes could be, with much clarity expected lone aft investors tin gully comparisons from Novartis’ (NVS) pelicarsen data.

Separately, connected January 6, Amgen said it volition get Dark Blue Therapeutics Ltd., a privately held biotech institution based successful the U.K. The transaction is valued astatine up to $840 million.

This woody strengthens Amgen’s oncology pipeline by adding an investigational tiny molecule aimed astatine degrading 2 proteins, MLLT1/3, which are believed to thrust definite forms of acute myeloid leukemia (AML), a fast-moving humor cancer. Amgen pointed to encouraging preclinical results successful leukemia models, showing anti-cancer enactment and a mechanics that appears chiseled from existing treatments. That differentiation could enactment some single-agent usage and combinations, particularly successful cases wherever absorption becomes a occupation and longer-lasting remission is the goal.

Amgen besides said it plans to integrate Dark Blue into its existing probe organization, which should further enactment its early-stage oncology find work.

Amgen Inc. (NASDAQ:AMGN) is simply a planetary biotech institution focused connected discovering, developing, manufacturing, and delivering innovative medicines for patients facing immoderate of the world’s toughest diseases.

While we admit the imaginable of AMGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: Dividend Contenders List: Top 20 Stocks and 12 Most Profitable Dividend Stocks to Buy successful 2026

Disclosure: None.